Leap Therapeutics (LPTX) Competitors $0.33 +0.00 (+1.39%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.09%) As of 07/15/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, VTVT, HOWL, ALGS, IPSC, ADVM, CELU, LIAN, KLRS, and ANVSShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), vTv Therapeutics (VTVT), Werewolf Therapeutics (HOWL), Aligos Therapeutics (ALGS), Century Therapeutics (IPSC), Adverum Biotechnologies (ADVM), Celularity (CELU), LianBio (LIAN), Kalaris Therapeutics (KLRS), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences vTv Therapeutics Werewolf Therapeutics Aligos Therapeutics Century Therapeutics Adverum Biotechnologies Celularity LianBio Kalaris Therapeutics Annovis Bio Leap Therapeutics (NASDAQ:LPTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to LPTX or DTIL? In the previous week, Precision BioSciences had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.87 beat Precision BioSciences' score of 0.61 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Very Positive Precision BioSciences Positive Is LPTX or DTIL more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -162.15% -120.05% Precision BioSciences -42.99%-69.26%-29.30% Do analysts rate LPTX or DTIL? Leap Therapeutics currently has a consensus target price of $3.38, indicating a potential upside of 908.37%. Precision BioSciences has a consensus target price of $47.00, indicating a potential upside of 956.18%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LPTX or DTIL? Leap Therapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Do insiders & institutionals hold more shares of LPTX or DTIL? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher earnings & valuation, LPTX or DTIL? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.70-0.20Precision BioSciences$68.70M0.72$7.17M-$2.01-2.21 SummaryPrecision BioSciences beats Leap Therapeutics on 10 of the 15 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.68M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.2020.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.377.568.145.54Net Income-$67.56M-$55.11M$3.24B$257.73M7 Day Performance-1.76%3.81%0.18%-0.08%1 Month Performance-14.68%11.60%5.96%8.09%1 Year Performance-85.06%-2.11%26.24%13.02% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.22 of 5 stars$0.33+1.4%$3.38+908.4%-84.6%$13.68MN/A-0.2040Positive NewsGap DownDTILPrecision BioSciences4.1648 of 5 stars$4.31-0.7%$47.00+990.5%-56.5%$48.12M$68.70M-2.14200VTVTvTv Therapeutics1.6058 of 5 stars$15.10+0.2%$35.50+135.2%-30.8%$48.14M$1.02M-5.019Positive NewsHOWLWerewolf Therapeutics3.91 of 5 stars$1.05-1.9%$8.33+693.7%-54.2%$48.01M$1.88M-0.6340ALGSAligos Therapeutics4.1494 of 5 stars$7.50-4.3%$70.00+833.3%-33.3%$47.94M$3.94M-0.4390IPSCCentury Therapeutics3.2441 of 5 stars$0.55-0.9%$4.20+663.5%-79.0%$47.83M$6.59M-1.90170News CoverageGap DownADVMAdverum Biotechnologies4.397 of 5 stars$2.23-2.2%$23.80+967.3%-69.7%$47.63M$1M-0.35190News CoverageCELUCelularity0.094 of 5 stars$1.82-8.1%N/A-22.3%$47.42M$54.22M-0.69220Upcoming EarningsGap UpLIANLianBioN/A$0.43+3.2%N/A+42.2%$46.82MN/A-0.53110KLRSKalaris TherapeuticsN/A$2.61+4.4%N/AN/A$46.76MN/A0.00110ANVSAnnovis Bio1.5527 of 5 stars$2.39+1.3%$18.00+653.1%-78.6%$45.99MN/A-1.113 Related Companies and Tools Related Companies Precision BioSciences Alternatives vTv Therapeutics Alternatives Werewolf Therapeutics Alternatives Aligos Therapeutics Alternatives Century Therapeutics Alternatives Adverum Biotechnologies Alternatives Celularity Alternatives LianBio Alternatives Kalaris Therapeutics Alternatives Annovis Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPTX Stock Alerts